Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 29, 2026, titled "OneSource s Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection".

Regulatory Product ApprovalBusiness Updates View source PDF

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-0.7%1-day move

₹1764.40

prior close

₹1819.30

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.6+0.2+0.2-0.0-0.7-0.8-0.3-1.2+2.8+1.9+5.6+1.2-8.8—

Up moveDown movePending

AI summary

OneSource Specialty Pharma's partner Dr. Reddy's Laboratories has received a Notice of Compliance from Health Canada for Generic Semaglutide Injection, which is a generic version of Novo Nordisk's diabetes drug Ozempic. OneSource serves as the CDMO (Contract Development and Manufacturing Organization) partner on this program, providing scale-up and commercial manufacturing services. The manufacturing will be done at OneSource's US-FDA approved facility in Bengaluru. This approval strengthens the existing collaboration between the two companies, combining Dr. Reddy's peptide development expertise with OneSource's manufacturing capabilities. No specific revenue or order value has been disclosed in the filing.

Likely market impact

This approval is positive for OneSource as it validates their CDMO capabilities and opens potential revenue streams from manufacturing generic semaglutide for the Canadian market. However, the impact remains limited until commercial supply actually begins and generates revenue.